By Andrew Wilson and Heather Easterling
Read time: 4 minutes
The 340B drug pricing program has evolved significantly since it was introduced in 1992. Health systems have grown more complex, covered entities have changed, and more. Within this time, specialty drug costs have skyrocketed, even as the total percentage of specialty drugs prescribed remains low. And the 340B program itself has become more difficult to navigate.
This white paper shares how health systems can approach specialty pharmacy operations to more effectively do the most good in their communities.